News / Health

    Malaria Vaccine Offers Hope

    This undated photo supplied by WGBH/Nova shows a mosquito at work.
    This undated photo supplied by WGBH/Nova shows a mosquito at work.

    Related Articles

    Study: Pregnant Women Not Gaining Access to Malaria Prevention

    Malaria infections, primarily in sub-Saharan Africa, responsible for deaths of some 200,000 newborns and 10,000 new mothers each year

    Audio Warmer Temps Trigger More Disease

    Scientists say climate change creating favorable environment for germs, pests
    VOA News
    An experimental malaria vaccine appears to offer protection against infection in healthy adults, according to U.S. researchers. The researchers also say early results indicate the vaccine is safe and “generated an immune response” in the group of volunteers tested.

    The vaccine, known as PfSPZ, is composed of live but weakened sporozoites of the species Plasmodium falciparum, the most deadly of the malaria-causing parasites.

    Malaria is transmitted to humans by the bite of an infected mosquito. After the bite occurs, infectious malaria parasites in the immature, sporozoite stage of their life cycle, first travel to the liver, where they multiply, and then spread through the bloodstream.

    “In this trial, we showed in principle that sporozoites can be developed into a malaria vaccine that confers high levels of protection and is made using the good manufacturing practices that are required for vaccine licensure,” said Dr. Robert A. Seder, chief of the Cellular Immunology Section of the NIAID Vaccine Research Center and principal investigator of the trial.

    One potential drawback to the vaccine is that it appeared most effective when administered intravenously because lower doses given under the skin did not yield similar results.

    “Despite this challenge, these trial results are a promising first step in generating high-level protection against malaria, and they allow for future studies to optimize the dose, schedule and delivery route of the candidate vaccine,” said Seder.

    Fifty-seven adults between 18 and 45 years old took part in Phase One of the trial. Forty received the vaccine and 17 did not. Some of those who received the vaccine were given increasing doses. After seven days of monitoring, “no severe adverse effects associated with the vaccine occurred, and no malaria infections related to vaccination were observed.”

    Furthermore, those who received the most vaccine generated more antibodies against malaria, researchers said.

    Three weeks after the last dosage, participants -- both those who received the vaccine and the control group -- were exposed to bites from five mosquitoes carrying the P. falciparum strain from which the PfSPZ Vaccine was derived.

    The researchers found that the higher dosages of PfSPZ Vaccine were associated with protection against malaria infection. Only three of the 15 participants who received higher doses of the vaccine became infected, compared to 16 of 17 participants in the lower dose group who became infected. Among the 12 participants who received no vaccine, 11 participants became infected, researchers said.

    Researchers say they plan several follow-up studies to test dosage schedules and whether larger doses delivered under the skin can offer the same immune response.

    “The global burden of malaria is extraordinary and unacceptable,” said Dr. Anthony Fauci, the NIAID director. “Scientists and health care providers have made significant gains in characterizing, treating and preventing malaria; however, a vaccine has remained an elusive goal. We are encouraged by this important step forward.”

    The vaccine was developed by scientists at Sanaria Inc. The clinical evaluation was conducted by researchers at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and their collaborators at the Walter Reed Army Institute of Research and the Naval Medical Research Center.

    The results of the study were published in the August 8 issue of Science.

    You May Like

    Ugandan Opposition Candidate: Only Intimidation, Vote Buying Can Prevent Victory

    Kizza Besigye says he has been drawing large crowds and claims he has widespred support ahead of Feb. 18 vote

    HRW: Both Sides in Ukraine Conflict Targeted, Used Schools

    Rights group documents how both sides in Ukraine conflict carried out attacks on schools and used them for military purposes

    Sanctions Just Got Real for Over 54,000 North Koreans

    Shuttering of Kaesong complex ends virtually any hope of peaceful settlement to long-standing tensions on Korean peninsula in near future

    This forum has been closed.
    Comment Sorting
    Comments
         
    by: Toogee from: South Lake Tahoe
    August 11, 2013 9:31 PM
    This pic shown is that of an Aedes aegypti, which vectors a few nasty pathogens like dengue fever, chikungunya and yellow fever, but isn't a primary vector of malaria, is it?

    by: kooni from: missipi
    August 11, 2013 6:50 PM
    they weren't actually bitten by the mosquito you idiot, there blood was tested with the malaria to see if the white cells respond to it.

    by: Cranksy from: USA
    August 09, 2013 1:31 PM
    "Three weeks after the last dosage, participants -- both those who received the vaccine and the control group -- were exposed to bites from five mosquitoes carrying the P. falciparum strain from which the PfSPZ Vaccine was derived." I read the linked material that stated "[t]his controlled human malaria infection procedure — a standard process in malaria vaccine trials...." Isn't this type of exposure considered unethical? Volunteers or not these people didn't simply remain or return to the places where they live their lives to be naturally exposed to P. falciparum "the most deadly form of the malaria-causing parasites."

    Featured Videos

    Your JavaScript is turned off or you have an old version of Adobe's Flash Player. Get the latest Flash player.
    Russia's Car Sales Shrink Overall, But Luxury and Economy Models See Growthi
    X
    February 10, 2016 5:54 AM
    Car sales in Russia dropped by more than a third in 2015 because of the country's economic woes. But, at the extreme ends of the car market, luxury vehicles and some economy brands are actually experiencing growth. VOA's Daniel Schearf reports from Moscow.
    Video

    Video Russia's Car Sales Shrink Overall, But Luxury and Economy Models See Growth

    Car sales in Russia dropped by more than a third in 2015 because of the country's economic woes. But, at the extreme ends of the car market, luxury vehicles and some economy brands are actually experiencing growth. VOA's Daniel Schearf reports from Moscow.
    Video

    Video Civil Rights Pioneer Remembers Struggle for Voting Rights

    February is Black History Month in the United States. The annual, month-long national observance pays tribute to important people and events that shaped the history of African Americans. VOA's Chris Simkins reports how one man fought against discrimination to help millions of blacks obtain the right to vote
    Video

    Video Jordanian Theater Group Stages Anti-Terrorism Message

    The lure of the self-styled “Islamic State” has many parents worried about their children who may be susceptible to the organization’s online propaganda. Dozens of Muslim communities in the Middle East are fighting back -- giving young adults alternatives to violence. One group in Jordan is using dramatic expression a send a family message. Mideast Broadcasting Network correspondent Haider Al Abdali shared this report with VOA. It’s narrated by Bronwyn Benito
    Video

    Video Migrant Crisis Fuels Debate Over Britain’s Future in EU

    The migrant crisis in Europe is fueling the debate in Britain ahead of a referendum on staying in the European Union that may be held this year. Prime Minister David Cameron warns that leaving the EU could lead to thousands more migrants arriving in the country. Meanwhile, tension is rising in Calais, France, where thousands of migrants are living in squalid camps. VOA's Henry Ridgwell reports.
    Video

    Video Valentine's Day Stinks for Lebanese Clowns

    This weekend, on Valentine's Day in Lebanon, love is not the only thing in the air. More than half a year after the country's trash crisis began, the stink of uncollected garbage remains on the streets. Step forward "Clown Me In," a group of clowns who use their skills for activism. Before the most romantic day of the year the clowns have released their unusual take on love in Lebanon -- in a bid to keep the pressure up and get the trash off the streets. John Owens reports from Beirut.
    Video

    Video Families Flee Aleppo for Kurdish Regions in Syria

    Not all who flee the fighting in Aleppo are trying to cross the border into Turkey. A VOA reporter caught up with several families heading for Kurdish-held areas of northern Syria.
    Video

    Video Rocky Year Ahead for Nigeria Amid Oil Price Crash

    The global fall in the price of oil has rattled the economies of many petroleum exporters, and Africa’s oil king Nigeria is no exception. As Chris Stein reports from Lagos, analysts are predicting a rough year ahead for the continent’s top producer of crude.
    Video

    Video 'No Means No' Program Targets Sexual Violence in Kenya

    The organizers of an initiative to reduce and stop rape in the informal settlements around Kenya's capital say their program is having marked success. Girls are taking self-defense classes while the boys are learning how to protect the girls and respect them. Lenny Ruvaga reports from Nairobi.
    Video

    Video Chocolate Lovers Get a Sweet History Lesson

    Observed in many countries around the world, Valentine’s Day is sometimes celebrated with chocolate festivals. But at a festival near Washington, the visitors experience a bit more than a sugar rush. They go on a sweet journey through history. VOA’s June Soh takes us to the festival.
    Video

    Video 'Smart' Bandages Could Heal Wounds More Quickly

    Simple bandages are usually seen as the first line of attack in healing small to moderate wounds and burns. But scientists say new synthetic materials with embedded microsensors could turn bandages into a much more valuable tool for emergency physicians. VOA’s George Putic reports.
    Video

    Video Researchers Use 3-D Printer to Produce Transplantable Body Parts

    Human organ transplants have become fairly common around the world in the past few decades. Researchers at various universities are coordinating their efforts to find solutions -- including teams at the University of Pennsylvania and Rice University in Houston that are experimenting with a 3-D printer -- to make blood vessels and other structures for implant. As VOA’s Greg Flakus reports from Houston, they are also using these artificial body parts to seek ways of defeating cancerous tumors.
    Video

    Video Helping the Blind 'See' Great Art

    There are 285 million blind and visually impaired people in the world who are unable to enjoy visual art at a museum. One New York photographer is trying to fix this situation by making tangible copies of the world’s masterpieces. VOA correspondent Victoria Kupchinetsky was there as visually impaired people got a feel for great art. Joy Wagner narrates her report.
    Video

    Video German Artists to Memorialize Refugees With Life Jacket Exhibit

    Sold in every kind of shop in some Turkish port towns, life jackets have become a symbol of the refugee crisis that brought a million people to Europe in 2015.  On the shores of Lesbos, Greece, German artists collect discarded life jackets as they prepare an art installation they plan to display in Germany.  For VOA, Hamada Elrasam has this report from Lesbos, Greece.
    Video

    Video E-readers Help Ease Africa's Book Shortage

    Millions of people in Africa can't read, and there's a chronic shortage of books. A non-profit organization called Worldreader is trying to help change all that one e-reader at a time. VOA’s Deborah Block tells us about a girls' school in Nairobi, Kenya where Worldreader is making a difference.